Pharma Stock Jumps After Securing ₹515 Cr Contracts from Malaysia’s Ministry of Health

Synopsis: Biocon strengthened its Malaysia presence after partner Duopharma secured insulin contracts worth over ₹514 crore, supporting affordable diabetes treatment and expanding patient access.

This Mid-Cap Pharma Stock, engaged in developing, manufacturing, and commercializing biosimilars, generic medicines, and specialty therapies, serving patients globally across diabetes, oncology, immunology, and other healthcare segments, is in focus after securing insulin supply contracts worth Rs. 520 Cr from the Ministry of Health Malaysia

With a market capitalization of Rs. 68,572.50 crores, the share of Biocon Limited has reached an intraday high of Rs. 428.40 per equity share, rising nearly 1.19 percent from its previous day’s close price of Rs. 423.35. Since then, the stock has retreated and is currently trading at Rs. 423.05 per equity share. 

What is the News?

Biocon Limited has strengthened its presence in Malaysia through its long-standing partnership with Duopharma Biotech, which has secured insulin supply contracts worth more than MYR 225 million (approximately Rs. 514.58 crore) from Malaysia’s Ministry of Health. 

Under these agreements, Biocon will supply human insulin, insulin glargine, and insulin aspart to support affordable diabetes treatment. The contracts include a 3-year agreement worth MYR 155.27 million (Rs. 353.05 crore) for human insulin, along with two 2-year contracts worth MYR 18 million (Rs. 40.99 crore) and MYR 52.5 million (Rs. 119.54 crore) for insulin glargine and insulin aspart, respectively.

Malaysia is a key market for Biocon, which operates one of Asia’s largest integrated insulin manufacturing facilities in Johor. The company has invested over USD 600 million in the facility since 2011 and employs more than 1,100 people. The plant has received approvals from major regulators, including the U.S. FDA, EMA, TGA, ANVISA, and Malaysia’s NPRA.

Over the past decade, Biocon and Duopharma have supplied more than 120 million insulin cartridges to Malaysian public healthcare facilities, benefiting over 450,000 patients. With an estimated 4.75 million people living with diabetes in Malaysia, the partnership plays an important role in improving access to high-quality and affordable insulin therapies while supporting the country’s healthcare system.

Business Highlights

Biocon Limited has a strong global presence in the biopharmaceutical industry, serving patients in more than 120 countries. The company has received over 215 cGMP approvals, serves 16 of the world’s top 20 pharmaceutical companies, and has reached more than 1,500 patients through its healthcare solutions. Biocon operates 11 manufacturing facilities worldwide, supporting the development and supply of high-quality and affordable medicines.

Company Overview

Biocon Limited is a leading global biopharmaceutical company headquartered in Bengaluru, India. The company is engaged in developing, manufacturing, and commercializing biosimilars, generic medicines, and specialty products for patients worldwide. 

Biocon Limited focuses on key therapeutic areas such as diabetes, oncology, immunology, cardiovascular diseases, and ophthalmology. With strong research capabilities and global manufacturing facilities, Biocon aims to make high-quality and affordable medicines accessible to patients across the world.

Recent Quarter Results

Coming into financial highlights, Biocon Limited’s revenue has increased from Rs. 4,417 crore in Q4 FY25 to Rs. 4,517 crore in Q4 FY26, which has grown by 2.26 percent. The net profit has decreased by 56.36 percent from Rs. 459 crore in Q4 FY25 to Rs. 199 crore in Q4 FY26.

Biocon Limited’s revenue has grown at a CAGR of 19 percent over the last five years. In terms of return ratios, the company’s ROCE and ROE stand at 3.75 percent and 1.40 percent, respectively. Biocon Limited has an earnings per share (EPS) of Rs. 2.38, and its debt-to-equity ratio is 0.45x.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps After Securing ₹515 Cr Contracts from Malaysia’s Ministry of Health appeared first on Trade Brains.